Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
Needham analyst forecasts a positive outlook for Arcellx Inc ACLX in 2024, citing strong potential stemming from the anticipated pivotal interim readout from the iMMagine-1 study, expected in the second half of 2024. This development is poised to bolster filing prospects for the company in 2025.…
#arcellxincaclx #arcellx #needham #aclx #overallresponserate #carvykti